Funding Wizard

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Technology-enhanced training products for the health and safety training of: hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biological hazard response, infectious disease response, and medical waste cleanup; emergency responders in disasters; and worker resiliency training. Technology-enhanced training products as defined by the Worker Training Program (WTP) include, but are not limited to, online training, mobile device training, virtual reality, and serious gaming. These advanced technologies complement all phases of training from development to evaluation and can enhance, supplement, improve, and provide health and safety training for hazardous materials workers. These products must complement the goals and objectives of WTP. The major objective of the NIEHS WTP is to prevent work related harm by training workers in how best to protect themselves and their communities from exposure to hazardous materials. The financial support for this initiative comes directly from NIEHS Worker Education and Training Branch SBIR funds.

This FOA solicits Research Education Grant (R25) applications to develop and implement a short course focused on (1) steps required for successful medical device development, translation, and commercialization (2) common technical and strategic challenges, and (3) best-practices and resources for each stage in the process. Applicants may choose to include an extended mentorship plan if they see fit. The short course should address a broad audience, including senior post-doctoral fellows, independent academic researchers, clinician scientists, and small business entrepreneurs interested in developing, translating, and/or commercializing medical devices to diagnose or treat a nervous system disorder.

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.

This Funding Opportunity Announcement (FOA) solicits applications from eligible institutions to develop a?Research Coordinating Center (RCC) to support the development of an NIH CCH Community of Practice by managing and supporting current and future CCH research and capacity building efforts. The RCC will create a robust inclusive CCH-COP that fosters collaboration, capacity building, innovation and research that aligns with the NIH CCH initiative. The RCC will offer opportunities for collaboration between multiple disciplines required to conduct solutions-driven research on the health impacts of climate change. The four functions of the RCC are administrative oversight, resource development, data management, and research capacity building.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Biomarker Characterization Centers (BCCs), one of the three scientific units of the Early Detection Research Network (EDRN). The EDRN is a national infrastructure to discover, develop, and validate biomarkers and imaging methods for early cancer detection and risk assessment. BCCs will (1) discover, develop, characterize and test new biomarkers or refine existing biomarkers, (2) develop, refine and/or standardize biomarker assays, (3) provide resources and support for the validation of biomarkers developed by the EDRN, and (4) participate in collaborative projects with other laboratories and centers.The other two scientific units of the continuing EDRN program are the Clinical Validation Centers (CVCs), which will conduct clinical research on the validation of biomarkers and will serve as resource centers for the Network by participating in collaborative biomarker validation studies with EDRN BCCs; and the Data Management and Coordinating Center (DMCC), which will support statistical and computational analyses, informatics infrastructure, study design, coordination and management of EDRN-sponsored biomarker validation studies, and the coordination of Network-wide meetings and workshops.

The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Center for International Blood and Marrow Transplant Research (CIBMTR) as a data resource enabling broad studies on Hematopoietic Stem Cell transplantation (HCT) and Adoptive Cellular Therapy (ACT) research. The CIBMTR represents a network comprised of more than 380 US and international transplant centers that submit outcome data for patients receiving cellular therapies. The CIBMTR Statistical Center provides data acquisition and management and information technology services to maintain a unique contemporary clinical outcomes' database and facilitates observational and interventional research through scientific and statistical expertise necessary to support analyses of these data. NIH is supporting the CIBMTR to ensure the database remains available to the public and to improve the treatment, survival, and quality of life for patients diagnosed with cancer and non-malignant blood disorders.

The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.

This funding opportunity announcement (FOA) seeks applicants experienced in the isolation and sequencing of RNA from brain-derived extracellular vesicles to develop a research resource for the Accelerating Medicines Partnership in Parkinson's Disease (AMP PD). Approximately 2400 blood samples will be provided for this project from existing Parkinson's disease and normal control cohorts that already have longitudinal clinical and sequencing data that is publicly available to interested researchers. It is intended that this resource will become a part of the AMP PD Knowledge Platform, where it will be broadly shared with the research community.